Position in NVS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$165,026
+$27,093 QoQ
Shares Held
1,053
+16.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#1,336
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026WPG Advisers, LLC holds $2,503,381 across 15 Drug Manufacturers - General names. NVS ranks #5 (6.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
2,994 | $760,386 | |
| 2 | LLY |
ELI LILLY & Co
|
404 | $484,569 | |
| 3 | MRK |
Merck & Co., Inc.
|
1,782 | $228,987 | |
| 4 | AZN |
Astrazeneca PLC
|
1,054 | $199,859 | |
| 5 | NVS |
Novartis AG
This page
|
1,053 | $165,026 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
2,626 | $151,310 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
871 | $110,042 | |
| 8 | ABBV |
AbbVie Inc.
|
395 | $99,397 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $165,026 | 1,053 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $137,933 | 903 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $58,043 | 421 | Shares | Sole | 2026-01-28 | |
| 2025-09-30 | $27,571 | 215 | Shares | Sole | 2025-10-29 | |
| 2025-06-30 | $26,017 | 215 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $25,417 | 228 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $36,199 | 372 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||